brodalumab   Click here for help

GtoPdb Ligand ID: 7540

Synonyms: AMG-827 | AMG827 | Kyntheum® | Lumicef® | Siliq®
Approved drug Immunopharmacology Ligand
brodalumab is an approved drug (Japan (2016), FDA (2017), EMA (2017))
Compound class: Antibody
Comment: Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases. It targets the interleukin 17 receptor A (IL17RA).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Bioactivity Comments
BLAST searches using the peptide sequences of the heavy and light chains of brodalumab link to patent US7767206 [7], and monoclonal antibody clone AMH14/AML14.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Interleukin 17 receptor A Primary target of this compound Hs Antibody Binding 9.2 pKd - 7
⤷ pKd 9.2 (Kd 6.9x10-10 M) [7]